Metabolic Pathway Linking Carnitine Synthesis to DNA Repair in Cancer

Researchers have uncovered a critical metabolic link between alpha-ketoglutarate (αKG) and the ability of cancer cells to repair damaged DNA. The study identifies that the enzyme trimethyllysine hydroxylase epsilon (TMLHE)—the rate-limiting step in carnitine synthesis—is essential for the survival of cancer cells that are otherwise proficient in homologous recombination (HR). By modulating this pathway, cells can maintain the histone acetylation levels necessary to facilitate efficient DNA repair.

Traditionally, αKG has been studied primarily for its role in demethylation processes. However, this research reveals that αKG also regulates site-specific histone acetylation through the production of carnitine. This mechanism is distinct from other known acetyl-CoA-generating pathways, highlighting a unique metabolic vulnerability. When this αKG–carnitine axis is disrupted, HR-proficient cells lose their ability to repair DNA damage, effectively rendering them sensitive to therapeutic agents that target DNA integrity.

The implications for oncology are significant, particularly for patients undergoing chemotherapy or radiation. Analysis of patient samples shows a clear correlation between high TMLHE levels, increased histone acetylation, and poorer progression-free survival. This suggests that the TMLHE pathway acts as a resistance mechanism, allowing tumors to withstand DNA-damaging treatments. By targeting this metabolic axis, clinicians may be able to induce HR deficiency in tumors, potentially sensitizing them to existing therapies and improving patient outcomes. This discovery opens a new frontier in cancer metabolism, shifting the focus toward metabolic interventions to overcome treatment resistance.